The Incidence of Fungal Infections in Patients Treated with Tocilizumab for Severe COVID-19 Pneumonia Requiring High Care or ICU Admission: A Retrospective Cohort Study
Abstract
Background: Critically ill COVID-19 patients often experience immune dysregulation, leading to cytokine release syndrome and an increased susceptibility to nosocomial infections, including invasive fungal infections. Early detection and treatment of fungal infections is paramount due to associated high mortality rates. Tocilizumab, an IL-6 receptor-blocking monoclonal antibody used in treating COVID-19 patients, has shown efficacy in managing the cytokine storm but is linked to a heightened risk of secondary fungal infections. Aims: This study aimed to investigate the association between Tocilizumab use and fungal infections in COVID-19 patients admitted to an ICU in South Africa. Methods: We conducted a retrospective cohort study at a private hospital in Johannesburg, South Africa, from April 2020 to August 2021. Data from 373 COVID-19 patients admitted to high care or ICU were analysed. Patients were categorized based on positive fungal cultures. Demographics, Tocilizumab usage, and relevant factors were collected from electronic databases. Results: Fungal infections were identified in 15.6% of the patients. Tocilizumab use did not significantly correlate with fungal infections (OR: 0.342 [95%CI: 0.115-1.019]; P=0.054). Factors associated with fungal infections included extended hospital stays (OR: 1.098 [95% CI: 1.038-1.163], P=0.050 and elevated D-dimer values (OR:1.20; [95% CI: 1.035-1.390]; P=0.015). Females were less likely to develop a fungal infection (OR:0.224;…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 19 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.